Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients

Effects of exosomes on pre-metastatic niche formation in tumors

(2019) Yaxin Guo et al.   Molecular Cancer

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

(2019) Mauro Poggio et al.   CELL

Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer

(2018) Jianwei Gao et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC

(2018) Marzia Del Re et al.   BRITISH JOURNAL OF CANCER

Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth

(2018) Yi Yang et al.   CELL RESEARCH

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

(2018) Laura Mezquita et al.   JAMA Oncology

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles

(2018) Franz L. Ricklefs et al.   Science Advances

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

(2018) Gang Chen et al.   NATURE

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer

(2017) Reinhard Büttner et al.   JOURNAL OF CLINICAL ONCOLOGY

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

(2017) Julie R Brahmer et al.   LANCET ONCOLOGY

Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer

(2017) Haipeng Xu et al.   Scientific Reports

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

(2017) Jun Zhou et al.   Cancer Immunology Research

Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms

(2017) Laurent Muller et al.   OncoImmunology

Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis

(2016) Annette Becker et al.   CANCER CELL

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Exosomes and tumor-mediated immune suppression

(2016) Theresa L. Whiteside   JOURNAL OF CLINICAL INVESTIGATION

P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894)

(2016) Gilberto De Lima Lopes et al.   Journal of Thoracic Oncology

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 expression in human cancers and its association with clinical outcomes

(2016) Jinming Yu et al.   OncoTargets and Therapy

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

Exosomes: Emerging biomarkers and targets for ovarian cancer

(2015) Maggie K.S. Tang et al.   CANCER LETTERS

Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis

(2015) Yan Li et al.   CELL RESEARCH

Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

(2015) Sonia A. Melo et al.   NATURE

Exosomes in bodily fluids are a highly stable resource of disease biomarkers

(2015) Stephanie Boukouris et al.   Proteomics Clinical Applications

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Hypoxic enhancement of exosome release by breast cancer cells

(2012) Hamish W King et al.   BMC CANCER

An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cells

(2010) Robbert van der Voort et al.   JOURNAL OF LEUKOCYTE BIOLOGY